This therapeutic administration of anti-IL-6 not only doubled the survival time (from PID 3 to PID 6) of the lethally challenged, but it also resulted in 50% of the animals surviving and recovering from infection, clearing all clinical signs by PID 10. This evidence concerns the gene IL6 and infection.